



EUROPEAN COMMISSION  
JOINT RESEARCH CENTRE  
Directorate F – Health and Food  
**Disease Prevention**

## **Annual Declaration of Interests<sup>1</sup> (DoI) form (v1, 30 June 2025)**

European Commission initiative on Breast Cancer (ECIBC)

**Please answer each of the questions below.**

**If the answer to any of the questions is "Yes"<sup>2</sup>, please complete the corresponding fields, describing the circumstances, as appropriate.**

**If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the ECIBC activities.**

**If you do not disclose relevant activities of interest for the ECIBC, your role may be revised.**

---

<sup>1</sup> According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

<sup>2</sup> Answering "Yes" to the questions on this form does not automatically limit your participation in the ECIBC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

<b>Name and Surname:</b>	<b>Mireille Broeders</b>
--------------------------	--------------------------

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>1. Do you have current investments<sup>3</sup> in a legal entity<sup>4</sup> with an interest related to breast cancer which either:</b> <ul style="list-style-type: none"> <li>• has a value of more than 10.000 EUR, or</li> <li>• entitles you to a voting right of 5% or more?</li> </ul>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of entity;</li> <li>• Place;</li> <li>• Type of entity: public, private.</li> </ul>	[Please describe your role.]

<sup>3</sup> **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

<sup>4</sup> **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.



Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>B. Consultancy, including advisory activities</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> <li>• Received amounts for remunerated activities.</li> </ul>	[Please describe your role.]
<b>C. Non-remunerated post</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'ye's, please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> </ul>	[Please describe your role.]
<b>D. Legal representation<sup>5</sup></b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> </ul>	[Please describe your role.]

<sup>5</sup> **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<p><b>3. Regarding research related to breast cancer within the past 5 years:</b></p> <p><b>A. Have you been an investigator in research studies on breast cancer?</b></p>	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	11/2023-11/2030	DENSE-2: CEM and abbreviated MRI for women with extremely dense breast tissue.	Co-PI. No results published yet.
		01/2023-01/2028	Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program	Project leader and PI. Protocol paper published. No results published yet.
		01/2023-01/2027	Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program	Project leader and PI. Protocol paper published. No results published yet.
		01/2021 – 12/2025	Breast CAalcification Risk Evaluation Study (Breast-CARE Study).	Co-PI. No results published yet.
		08/2020 – 05/2025	aiREAD – Accurate and Intelligent Reading for Earlier breast cancer Detection.	Co-PI. Several papers published and abstracts accepted for conferences.
		06/2019 – 05/2023	Combining features from in-depth mammography analysis and pathology to optimize referral of possible invasive breast cancers at screening (IMAGINE).	Project leader and PI. First paper published. Abstracts accepted for conferences.
		03/2016 – 12/2021	Early detection of breast cancer – from one-size-fits-all to Personalised RISK-based MAMmography screening(PRISMA).	Project leader and PI. Abstracts accepted for conferences. No results published yet.
		06/2013 – 12/2021	Breast cancer screening – from a one-size-fits-all to a personalised risk-based approach.	Project leader and PI. Abstracts accepted for conferences. No results published yet.

<p><b>B. If yes, for the aforementioned research studies, did you receive support<sup>6</sup>?</b></p>	Yes <input checked="" type="checkbox"/>	11/2023-11/2030	Grant, ZonMw Vroege Opsporing, Den Haag, public, 4.4 M EUR. In-kind co-funding from vendors being negotiated.	DENSE-2: CEM and abbreviated MRI for women with extremely dense breast tissue.
	No <input type="checkbox"/>	01/2023-01/2028	Grant, KWF Dutch Cancer Society, Amsterdam, private, EUR 734.538. In-kind co-funding from vendors 1.321.600 EUR.	Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program
		01/2023-01/2027	Grant, ZonMw Vroege Opsporing, Den Haag, public, EUR 599.110. In-kind co-funding from vendors 248.000 EUR.	Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program
		01/2021 – 12/2024	Grant, ZonMw Vroege Opsporing, Den Haag, public, EUR 400.000.	Breast Calcification Risk Evaluation Study (Breast-CARE Study).
		08/2020 – 11/2024	Grant, KWF Dutch Cancer Society, NWO Domain AES, and Top Sector LSH, Technology for Oncology II, public/private, EUR 1.183.000.	aiREAD – Accurate and Intelligent Reading for Earlier breast cancer Detection.
		06/2019 – 05/2023	Grant, KWF Dutch Cancer Society, Amsterdam, private, EUR 730.260.	Combining features from in-depth mammography analysis and pathology (IMAGINE).
		03/2016 – 12/2021	Grant, KWF Dutch Cancer Society, Amsterdam, private, EUR 569.900.	Early detection of breast cancer – PRISMA
		06/2013 – 12/2021	Grant, ZonMw, programma TOP Preventie, Den Haag, public, EUR 674.659.	Breast cancer screening – from a one-size-fits-all to a personalised risk-based approach.
<p>European Commission - Joint Research Centre <input type="checkbox"/> via E. Fermi, 2749 <input type="checkbox"/> I-21027 Ispra (VA), Italy <input type="checkbox"/> TP 127  JRC-CANCER-POLICY-SUPPORT@ec.europa.eu</p>				
6				

---

<sup>6</sup> **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).



Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>5. Do you have intellectual property rights (IPR)<sup>8</sup> related to breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]
<b>6. Within the past 5 years:</b>				
<b>A. Have you provided any expert opinion or testimony in the field of breast cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
<b>B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]

<sup>7</sup> **Organisation** refers to a governmental, international or non-profit organisation.

<sup>8</sup> **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>7. Do any of your immediate family members<sup>9</sup> have direct interests related to breast cancer that could undermine your independence?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]
<b>8. Within the past 5 years, did you take part in other activities with interests related to breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the activity.	[Please describe the activity.]

---

<sup>9</sup> **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

**Notes:**

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published<sup>10</sup> before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: [JRC-CANCER-POLICY-SUPPORT@ec.europa.eu](mailto:JRC-CANCER-POLICY-SUPPORT@ec.europa.eu).

- I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the ECIBC membership<sup>11</sup>.
- I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725<sup>12</sup>.

**Name and Surname:** Mireille Broeders

**Date:** 10 September 2025

**Signature:**

**Place:** Nijmegen, the Netherlands



---

<sup>10</sup> Personal data processing including the DoI

<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

<sup>11</sup> Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

<sup>12</sup> Protection of individuals with regard to the processing of personal data

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>